Boston Scientific buys nVision Medical for $275 million
Boston Scientific Corp. said Monday that it has bough nVision Medical Corp., a California med-tech firm that's developing a device to screen women for ovarian cancer.
The Star Tribune reports on the deal by Massachusetts-based Boston Scientific (NYSE: BSX), which will pay $150 million upfront and another $125 million in later payments to acquire nVision.
RELATED: Read Boston Scientific's full announcement
The company sees a near-term market potential of abou t $500 million per year for nVision's…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Mark Reilly Source Type: news
More News: American Health | Cancer | Cancer & Oncology | Health Management | Ovarian Cancer | Ovaries | Women